CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling
出版年份 2019 全文链接
标题
CDK
12 drives breast tumor initiation and trastuzumab resistance via
WNT
and
IRS
1‐ErbB‐
PI
3K signaling
作者
关键词
-
出版物
EMBO REPORTS
Volume -, Issue -, Pages -
出版商
EMBO
发表日期
2019-08-30
DOI
10.15252/embr.201948058
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Target Gene Screening: a web application for breast cancer target gene screening using multi-omics data analysis
- (2019) Hyung-Yong Kim et al. BRIEFINGS IN BIOINFORMATICS
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
- (2018) W Shi et al. ANNALS OF ONCOLOGY
- Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
- (2018) Srinivas R. Viswanathan et al. CELL
- A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases
- (2018) Yiqun Zhang et al. Cell Reports
- Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer
- (2017) Hee-Joo Choi et al. JNCI-Journal of the National Cancer Institute
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
- (2017) Kalnisha Naidoo et al. MOLECULAR CANCER THERAPEUTICS
- CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
- (2017) Jerry F. Tien et al. NUCLEIC ACIDS RESEARCH
- Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer
- (2017) Hee-Joo Choi et al. JNCI-Journal of the National Cancer Institute
- Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
- (2016) Andrew R. Green et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteogenomics connects somatic mutations to signalling in breast cancer
- (2016) Philipp Mertins et al. NATURE
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
- (2016) Tinghu Zhang et al. Nature Chemical Biology
- A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
- (2016) Anthony Ferrari et al. Nature Communications
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- Targeting HER2 for the Treatment of Breast Cancer
- (2015) Mothaffar F. Rimawi et al. Annual Review of Medicine
- The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells
- (2015) KATJA STORCH et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- MEL-18 loss mediates estrogen receptor–α downregulation and hormone independence
- (2015) Jeong-Yeon Lee et al. JOURNAL OF CLINICAL INVESTIGATION
- HER2-directed therapy: current treatment options for HER2-positive breast cancer
- (2015) Shahid Ahmed et al. Breast Cancer
- DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression
- (2015) Min-Hyung Cho et al. Nature Communications
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
- (2014) C. Saura et al. CLINICAL CANCER RESEARCH
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
- (2014) Rachael Natrajan et al. JOURNAL OF PATHOLOGY
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Cancer stemness in Wnt-driven mammary tumorigenesis
- (2013) Joana Monteiro et al. CARCINOGENESIS
- Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice
- (2013) K Watanabe et al. ONCOGENE
- Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer
- (2012) A-Ram Choi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene
- (2012) Makoto Saito et al. FEBS LETTERS
- Expression of Wnt3 Activates Wnt/ -Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells
- (2012) Y. Wu et al. MOLECULAR CANCER RESEARCH
- The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
- (2012) Kristine Kleivi Sahlberg et al. Molecular Oncology
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Differential analysis of gene regulation at transcript resolution with RNA-seq
- (2012) Cole Trapnell et al. NATURE BIOTECHNOLOGY
- bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
- (2011) Pascal Jézéquel et al. BREAST CANCER RESEARCH AND TREATMENT
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
- (2011) D. Blazek et al. GENES & DEVELOPMENT
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Genome profiling of ERBB2-amplified breast cancers
- (2010) Fabrice Sircoulomb et al. BMC CANCER
- CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
- (2010) B. Bartkowiak et al. GENES & DEVELOPMENT
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
- (2010) Cole Trapnell et al. NATURE BIOTECHNOLOGY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy
- (2008) Madhuri Kakarala et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now